NT5E and cancer: Although adenosine blockade has not been clinically tested in patients receiving RT, inhibitors of both adenosine conversion (anti-CD73 monoclonal antibodies) and adenosine uptake (A2AR-inhibitors) have been tested for safety and tolerability in patients with cancer and Parkinson’s disease, respectively (NCT02503774, NCT01283594).